Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to email@example.com so that we can defer those challenges. Your health and safety are paramount to us.
Posted 03 August 2012
Cass Sunstein, the high-profile director of the Office of Management and Budget's (OMB) Office of Information and Regulatory Affairs (OIRA), is set to resign from his position as the US' regulatory czar and return to teaching at Harvard University, reports Politico.
Advanced remarks made available to Politico from President Barack Obama said Sunstein had been instrumental in, "Eliminating tens of millions of hours of paperwork burdens for our nation's citizens and businesses, [showing] that it is possible to support economic growth without sacrificing health, safety, and the environment."
"Cass has shepherded our review of existing rules to get rid of those that cost too much or no longer make sense, an effort that is already on track to save billions of dollars," Obama said. "With these reforms and his tenacious promotion of cost-benefit analysis, his efforts will benefit Americans for years to come."
Sunstein's tenure at the agency hasn't been without controversy, either in general or with regard to the US Food and Drug Administration (FDA). Liberal critics of the agency have been frustrated with its approach to regulatory policy-deemed to lean toward industry-observed Politico. The agency, which must approve all proposed final rules before they are allowed to come into effect, was also involved in lengthy holds on several FDA regulations, including the Unique Device Identification (UDI) rule and a rule on performance standards for laser products.
A Void in Permanent Leadership?
It remains unclear whether the White House will be able to easily appoint a new director to OIRA. Under federal rules, the head of OIRA must be confirmed by the Senate, where even a single senator can place a hold on a confirmation proceeding and delay a vote for months or longer. Given the high-profile status of the office and its impact on regulations, OIRA may be without a permanent director for some time.
According to OIRA's webpage, its second-in-comment after Sunstein is Associate Administrator Jeff Weiss, who would likely be made Acting Director in the meantime.
Politico - Exclusive: 'Regulatory czar' Cass Sunstein returning to Harvard
Tags: Step Down, Resign, Regulatory Review, Sunstein, OIRA, OMB, Latest News, Obama, regulatory